Chemotherapy News and Research

Latest Chemotherapy News and Research

Celldex third quarter net loss increases to $9.1 million

Celldex Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2010. Celldex reported a net loss of $9.1 million, or $0.28 per share, for the third quarter of 2010 compared to a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009. For the nine months ended September 30, 2010, Celldex reported a net loss of $25.2 million, or $0.79 per share, compared to a net loss of $23.6 million, or $1.49 per share, for the nine months ended September 30, 2009.

2 Nov 2010

New targeted therapy shows positive results in patients with lung cancer

A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

2 Nov 2010

New REACT medical trial for early diagnosis of lung cancer

Physicians at El Camino Hospital are starting a medical trial called REACT that they hope may give doctors a new and cost-effective tool for early diagnosis of lung cancer, the deadliest of the common cancers.

2 Nov 2010

Novel technology using quantum dots increases drug uptake in lung injury

Researchers at the University at Buffalo have developed a novel technology using quantum dots that is expected to have major implications for research and treatment of tuberculosis, as well as other inflammatory lung diseases.

2 Nov 2010

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

The American Association of Acupuncture and Oriental Medicine (AAAOM) and the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM) are collaborating to respond to a recent report by British professor Edzard Ernst, published in The Guardian, claiming improperly trained acupuncture treatments have been the cause of deaths over the past 45 years.

2 Nov 2010

EMA issues Scientific Advice to Genta's clinical development plan for tesetaxel in patients with gastric cancer

Genta Incorporated today announced that the Company has received Scientific Advice from the European Medicines Agency (EMA) on the Company's clinical development plan for tesetaxel in patients with advanced gastric cancer, which includes a pivotal, randomized, controlled, Phase 3 trial.

2 Nov 2010

Study finds invasive patterns of lung cancer in pediatric patients

Because primary lung adenocarcinoma is exceedingly rare in the pediatric population, it is difficult to properly classify certain lung tumors in children and adolescents. While anecdotal reports of pediatric patients with lung cancer lesions exist, little research has been conducted to link the disease in children to similar pulmonary malignancies in adults.

2 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the Gynecologic Oncology Group (GOG) will initiate a Phase 2 clinical trial of elesclomol in combination with paclitaxel for the treatment of persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.

1 Nov 2010

Study finds SBRT therapy delays pancreatic cancer progression

For pancreatic cancer patients unable to undergo surgery the only known cure for this form of cancer a highly targeted cancer radiation therapy may help slow cancer progression and lessen disease symptoms, according to researchers at Henry Ford Hospital in Detroit.

30 Oct 2010

NeoPharm enters merger agreement with Insys Therapeutics

NeoPharm, Inc. a biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for cancer and other diseases, today announced it has entered into a merger agreement with Insys Therapeutics, a Phoenix-based drug development company focused on pain and oncology.

30 Oct 2010

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Noble metals such as platinum and palladium are becoming increasingly important because of growth in environmentally friendly applications such as fuel cells and pollution control catalysts. But the world has limited quantities of these materials, meaning manufacturers will have to rely on efficient recycling processes to help meet the demand.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Fast Neutron Radiotherapy safe and effective for treatment of non-small cell lung cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM) in Detroit are presenting two research studies that found the use of Fast Neutron Radiotherapy (FNRT) – a form of radiation that is about three times more powerful than typical photon radiotherapy – is highly effective and safe for patients who are dealing with non-small cell lung cancer. The findings are being formally presented Monday, Nov. 1, at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

Pro-Pharmaceuticals ships first commercial order of DAVANAT to PROCAPS in Colombia

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has shipped its first commercial order of DAVANAT® to PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. The $200,000 shipment of DAVANAT® will be used by PROCAPS to qualify its vial filling process.

28 Oct 2010

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Pfizer Inc. announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New England Journal of Medicine.

28 Oct 2010

Systemic amyloidosis patient to receive triple organ transplant

In 2005, then 40-year-old Walt McGuire was playing hockey twice a week, working full-time and chasing his young daughter. Then one day, he noticed after one trip up the stairs to catch her, he couldn't catch his breath. A few days later his legs were swollen. After numerous trips to different doctors, McGuire finally was diagnosed with a rare blood disorder called amyloidosis.

28 Oct 2010

Experts urge clinicians to discuss sperm banking with male cancer patients

Many men whose fertility may be at risk from cancer treatment are not being offered the chance to store their sperm according to new research published today in the Annals of Oncology (Thursday).

28 Oct 2010

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

Advanced procedure for microsurgical breast reconstruction offered at Baptist Health hospitals

When pediatrician Julie A. Buckley, MD, learned that she had breast cancer last year, she chose breast reconstruction using the “DIEP flap” procedure. DIEP (Deep Inferior Epigastric Artery Perforator) flap is available mainly at regional academic centers in the United States.

27 Oct 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Celldex third quarter net loss increases to $9.1 million

New targeted therapy shows positive results in patients with lung cancer

New REACT medical trial for early diagnosis of lung cancer

Novel technology using quantum dots increases drug uptake in lung injury

AAAOM, NCCAOM respond to report on cause of deaths due to improper acupuncture treatments

EMA issues Scientific Advice to Genta's clinical development plan for tesetaxel in patients with gastric cancer

Study finds invasive patterns of lung cancer in pediatric patients

New findings pave way to improve early detection of ovarian cancer

GOG to initiate combination elesclomol-paclitaxel Phase 2 clinical trial for ovarian cancer

Study finds SBRT therapy delays pancreatic cancer progression

NeoPharm enters merger agreement with Insys Therapeutics

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Novel small molecule inhibitors may provide new therapy for colon cancer

Fast Neutron Radiotherapy safe and effective for treatment of non-small cell lung cancer: Study

Pro-Pharmaceuticals ships first commercial order of DAVANAT to PROCAPS in Colombia

Pfizer announces publication of crizotinib data for NSCLC patients in New England Journal of Medicine

Systemic amyloidosis patient to receive triple organ transplant

Experts urge clinicians to discuss sperm banking with male cancer patients

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

Advanced procedure for microsurgical breast reconstruction offered at Baptist Health hospitals

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in